Satralizumab reduces relapse in some patients with neuromyelitis optica spectrum disorder

Satralizumab added to immunosuppressant treatment may reduce relapse in some cases of neuromyelitis optica spectrum disorder.
The phase 3, randomized, double-masked, placebo-controlled SAkuraSky trial included 83 patients randomly assigned 1:1 to receive satralizumab (Genentech) or placebo in addition to baseline immunotherapy treatment. Eight of 41 patients (20%) who received satralizumab relapsed compared with 18 of 42 patients (43%) who received placebo.
Satralizumab is a monoclonal antibody that targets the interleukin-6 receptor, which is thought to be a key driver of the inflammation that

Full Story →